Pancreatic Cancer News and Research

RSS
Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.
Tumor Biology Center to initiate Phase 2 clinical trial with CytRx’s INNO-206

Tumor Biology Center to initiate Phase 2 clinical trial with CytRx’s INNO-206

New project analyzes genetic sequence and variations of every gene expressed by 1,000 tumors

New project analyzes genetic sequence and variations of every gene expressed by 1,000 tumors

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

FDA Advisory Committee votes against the approval of Tarceva

FDA Advisory Committee votes against the approval of Tarceva

Ted and Jane Von Voigtlander Foundation gifts $15 million to University of Michigan Health System

Ted and Jane Von Voigtlander Foundation gifts $15 million to University of Michigan Health System

Eli Lilly provides financial guidance for 2010

Eli Lilly provides financial guidance for 2010

Event proceeds to benefit Virginia G. Piper Cancer Center at Scottsdale Healthcare

Event proceeds to benefit Virginia G. Piper Cancer Center at Scottsdale Healthcare

Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience

Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience

Positive clinical data from Phase II study of elacytarabine in patients with AML reported

Positive clinical data from Phase II study of elacytarabine in patients with AML reported

ImmunoCellular Therapeutics options immunotherapy targeting CSCs using abnormal Notch and Numb pathways

ImmunoCellular Therapeutics options immunotherapy targeting CSCs using abnormal Notch and Numb pathways

New study reveals smokeless tobacco products contain high levels of cancer-causing substances

New study reveals smokeless tobacco products contain high levels of cancer-causing substances

Protein marker may hold the key against pancreatic cancer

Protein marker may hold the key against pancreatic cancer

Researchers develop new application for improved detection of breast cancer cells

Researchers develop new application for improved detection of breast cancer cells

Cancer researchers find a way to turn ineffective new cancer drugs into cancer-fighters

Cancer researchers find a way to turn ineffective new cancer drugs into cancer-fighters

New finding reveals Barrett's esophagus in asymptomatic women undergoing endoscopic screening

New finding reveals Barrett's esophagus in asymptomatic women undergoing endoscopic screening

Clavis Pharma signs drug development and commercialisation agreement with Clovis Oncology

Clavis Pharma signs drug development and commercialisation agreement with Clovis Oncology

Clavis Pharma announces $380 million agreement to develop its CP-4126 drug candidate

Clavis Pharma announces $380 million agreement to develop its CP-4126 drug candidate

Study reveals effectiveness of radiation therapy in achieving local control and palliation in patients with PNTs

Study reveals effectiveness of radiation therapy in achieving local control and palliation in patients with PNTs

Quit smoking and get Karen Sokolof Javitch's "STAR TRACKS - THE TRIBUTE ALBUM" CD for free

Quit smoking and get Karen Sokolof Javitch's "STAR TRACKS - THE TRIBUTE ALBUM" CD for free

New studies suggest elevated risk of gastrointestinal cancers in diabetic patients

New studies suggest elevated risk of gastrointestinal cancers in diabetic patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.